Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Brilinta

- PMLiVE

AstraZeneca sales hit by Seroquel generics

End of patent exclusivity for antipsychotic among key factors dragging down revenues

- PMLiVE

AstraZeneca supports NHS medication passport app

Backs NIHR-NHS initiative under joint working agreement

- PMLiVE

AstraZeneca signs $200m deal with Bind for cancer drug

Follows deals with Amgen and Pfizer for Bind involving its Accurin nanotechnology

- PMLiVE

AstraZeneca signs cancer biomarkers discovery deal

Partners with UK firm on personalised oncology drug research

- PMLiVE

AZ boosts cardiovascular pipeline with US biotech acquisition

Its MedImmune biologics arm buys AlphaCore Pharma

- PMLiVE

AstraZeneca hit by US Pulmicort patent ruling

Federal court says patent for inhaled steroid drug is invalid

- PMLiVE

AstraZeneca settles with generic rivals in Crestor patent challenge

Blocks competition in US until May 2016

- PMLiVE

Additional 2,300 jobs to go at AstraZeneca

Soriot sets out strategy to return to growth

- PMLiVE

AstraZeneca cuts 1,600 jobs in overhaul of global operations

US and UK affected as Soriot pushes ahead with R&D restructuring

- PMLiVE

AZ loses Crestor patent battle in Australia

Follows challenge from Apotex

- PMLiVE

AZ in atherosclerosis education drive during US Heart Month

Encouraging the public to learn more about the causes of heart disease

- PMLiVE

US appeals court upholds AstraZeneca’s Seroquel XR patent

Says patent on unique formulation of antidepressant is valid

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links